Ausgabe Sonderheft 2/2009
Second line treatments for multiple sclerosis: benefits and risks
Inhalt (7 Artikel)
MS Treatment
Safety profile of Tysabri: international risk management plan
P. Iaffaldano, M. D’Onghia, Maria Trojano
MS Treatment
The pharmacovigilance program on natalizumab in Italy: 2 years of experience
G. Tedeschi, M. P. Amato, R. D’Alessandro, F. Drago, C. Milanese, P. Popoli, P. Rossi, G. Savettieri, M. R. Tola, N. Vanacore, A. Covezzoli, M. De Rosa, G. Comi, Carlo Pozzilli, Antonio Bertolotto, Maria Giovanna Marrosu, Luigi M. E. Grimaldi, C. Piccinni, N. Montanaro, Laura Periotto, Rosamaria Iommelli, Antonio Addis, Nello Martini, L. Provinciali, G. L. Mancardi
MS Treatment
Mitoxantrone: benefits and risks in multiple sclerosis patients
V. Martinelli, M. Radaelli, L. Straffi, M. Rodegher, G. Comi
MS Treatment
Cyclophosphamide as second-line therapy in multiple sclerosis: benefits and risks
Luciano Rinaldi, P. Perini, M. Calabrese, P. Gallo
MS Treatment
Autologous haematopoietic stem-cell transplantation in multiple sclerosis: benefits and risks
E. Capello, L. Vuolo, F. Gualandi, M. T. Van Lint, L. Roccatagliata, L. Bonzano, M. Pardini, A. Uccelli, Gianluigi Mancardi